MM 07

Research use only, not for human use.

Apelin biased agonist; exhibits bias for the G protein pathway. Stimulates endothelial NOS phosphorylation and expression, promotes proliferation, and attenuates apoptosis of human pulmonary arterial endothelial cells in vitro. Shows positive inotropic and vasodilatory effects in vivo and improves cardiac structure and function in a model of pulmonary arterial hypertension.

Apelin biased agonist; exhibits bias for the G protein pathway. Stimulates endothelial NOS phosphorylation and expression, promotes proliferation, and attenuates apoptosis of human pulmonary arterial endothelial cells in vitro. Shows positive inotropic and vasodilatory effects in vivo and improves cardiac structure and function in a model of pulmonary arterial hypertension.

MM 07 competes with nanomolar affinities for binding of [Glp65,Nle75,Tyr77] [125I]apelin-13 to human apelin receptors in CHO-K1 cells (KD, 300 nM) and human heart (KD, 172 nM, n=3).

MM 07 causes a dose-dependent increase in cardiac output, and although there is a decrease in vascular resistance, this is without corresponding effects on BP. Administration of SNAP produces a profound fall in BP in both [Pyr1]apelin-13 and MM 07-treated groups; however, although cardiac output is significantly increased in response to SNAP in the MM 07 group, it is significantly reduced in the [Pyr1]apelin-13 group. Neither peptide causes a significant change in heart rate, respiratory rate, or temperature. Both [Pyr1]apelin 13 and MM 07 increases peak velocity above basal levels.

——

Others

Other Targets

——

——

——

1876450-21-3

1539.89

C67H106N22O14S3

>98% (HPLC)

water:2 mg/mL

O=C(N(CCC1)[C@@H]1C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)[C@H](CCSC)NC([C@H](CCC3)N3C(CNC([C@H](CCCCN)NC([C@@H](NC([C@H](CSSC[C@@H](C(N[C@@]4([H])CCCNC(N)=N)=O)N)NC([C@](NC([C@@H](NC([C@@](CCC5)([H])N5C4=O)=O)CCCNC(N)=N)=O)([H])CC(C)C)=O)=O)CC6=CN=CN6)=O)=O)=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years